Pancreatic Cancer Research

ResearcherUniversity of ArizonaActive in the last 2 years

John C. Mansour

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6346-9429; OpenAlex author ID A5053019255. Sources: ClinicalTrials.gov.

Their work

Papers
12
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 12

  1. Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-3582↗
  2. Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.022↗
  3. Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? Co-author DOI 10.1245/s10434-023-13308-7↗
  4. Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. Co-author DOI 10.1245/s10434-019-08096-y↗
  5. Fasting and Glucose-Stimulated Changes in Plasma Glucagon in Pancreatic Cancer: Potential Biomarkers for Detection? Co-author DOI 10.1097/mpa.0000000000001208↗
  6. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2019.7322↗
  7. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Co-author DOI 10.1136/gutjnl-2016-313133↗
  8. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2018.7068↗
  9. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Co-author DOI 10.1200/jco.2016.68.5081↗
  10. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Co-author DOI 10.1038/ncomms7744↗
  11. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Co-author DOI 10.18632/oncotarget.3819↗
  12. Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer. Co-author DOI 10.1186/1748-717x-6-146↗

Trials 1

  1. Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer Principal investigator NCT01025882↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adam Charles Yopp · 7 shared papers, 2015–2025 · strength 0.85
  2. Patricio Marcelo Polanco · 6 shared papers, 2017–2025 · strength 0.81
  3. Matthew R. Porembka · 6 shared papers, 2017–2025 · strength 0.81
  4. Herbert J. Zeh · 5 shared papers, 2019–2025 · strength 0.76
  5. Sam C. Wang · 5 shared papers, 2017–2024 · strength 0.63
  6. Muhammad Shaalan Beg · 3 shared papers, 2019–2025 · strength 0.36
  7. Nina Niu Sanford · 2 shared papers, 2019–2025 · strength 0.28
  8. Todd Anthony Aguilera · 2 shared papers, 2019–2025 · strength 0.28
  9. Caitlin A. Hester · 2 shared papers, 2020–2023 · strength 0.28
  10. Amr I. Al Abbas · 1 shared paper, 2024 · strength 0.21
  11. Emile Farah · 1 shared paper, 2024 · strength 0.21
  12. Ahmed M. Elamir · 1 shared paper, 2025 · strength 0.18
  13. Syed Mohammad Ali Kazmi · 1 shared paper, 2025 · strength 0.18
  14. Zhikai Chi · 1 shared paper, 2025 · strength 0.18
  15. Peter Q. Leung · 1 shared paper, 2025 · strength 0.18
  16. Megan Wachsmann · 1 shared paper, 2025 · strength 0.18
  17. Salwan S. Al Mutar · 1 shared paper, 2025 · strength 0.18
  18. Erik S. Knudsen · 3 shared papers, 2015–2018 · strength 0.18
  19. Agnieszka Katarzyna Witkiewicz · 3 shared papers, 2015–2018 · strength 0.18
  20. Gilbert Zvikomborero Murimwa · 1 shared paper, 2023 · strength 0.17
  21. Ali A. Mokdad · 2 shared papers, 2017–2018 · strength 0.15
  22. Javier E. Ordonez · 1 shared paper, 2020 · strength 0.11
  23. David Jonathan Sher · 1 shared paper, 2019 · strength 0.10
  24. Charles J. Yeo · 2 shared papers, 2015 · strength 0.09
  25. Jennifer H. Stern · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.